期刊文献+

联合检测HE4和CA125对卵巢癌早期评估的价值 被引量:12

Value of Combined Detection of HE4 and CA125 in Early Diagnosis of Ovarian Cancer
下载PDF
导出
摘要 为探讨联合检测人附睾蛋白4(HE4)和糖类抗原125(CA125)在卵巢癌早期诊断、治疗中的价值,测定134例女性血清HE4、CA125水平,其中体检健康女性58名,作为正常对照组,盆腔肿物住院患者76例,按术后病理结果分为良性病变组15例,交界性病变组19例和卵巢癌组42例。应用ELISA法检测血清HE4水平,应用全自动化学发光分析系统检测血清CA125水平。全部随访2~62个月。卵巢癌组HE4、CA125水平明显高于其他3组,差异有统计学意义(P〈0.01),其他3组CA125水平比较差异均无统计学意义(P〉0.05),交界性病变组HE4水平与良性病变组、正常对照组比较,差异也有统计学意义(P〈0.05);二者水平在I期与Ⅲ、Ⅳ期之间差异有统计学意义(P〈0.05);且有淋巴结转移者明显高于无淋巴结转移者(P〈0.05);随访结果表明,随HE4和CA125水平的差异(P〈0.05),患者的5年生存率也有显著差异。对临床指标肿瘤长径〉6 cm的HE4水平明显高于肿瘤长径≤6 cm者(P〈0.05),而两者间CA125水平无显著差异(P〉0.05)。卵巢癌患者HE4和CA125水平呈正相关(r=0.48)。联合检测HE4和CA125对卵巢癌早期诊断,判断恶性程度,评价治疗效果及评估预后均有重要意义。 To explore the clinical value of combined detection of human epididymis gene product 4(HE4)and cancer antigen 125(CA125)in the early diagnosis of ovarian cancer,the serum HE4 and CA125 levels in 76 patients and 58 health controls were measured by enzyme-linked immunosorbent assay(ELISA)and automated chemiluminescence analysis system respectively.The 76 patients were divided into benign lesion group(15 cases),borderline lesion group(19 cases)and ovarian cancer group(42 cases)according to surgery pathological findings.The results showed that the serum HE4 and CA125 levels in ovarian cancer group were significantly higher than that of controls and other two patient groups(P0.01);The CA125 levels in other 3 groups had no statistically difference(P 0.05).There were statistically difference in serum HE4 levels between borderline lesion group and benign lesions,normal control group(P0.05).The serum HE4 levels in phase I were statistically different with that in phase Ⅲ and phase Ⅳ(P0.05).The serum HE4 levels in lymph node metastasis was significantly higher than those without lymph node metastasis(P0.05).Follow-up results showed that there was a significant difference in 5-year survival rate of patients as the difference of serum HE4 and CA125 levels(P0.05).The serum HE4 levels in those patients whose tumor size larger than 6cm were significantly higher than in those tumor size smaller than 6cm(P0.05),while their serum CA125 levels were no significant difference(P 0.05).There was a positive correlation between serum HE4 and CA125 levels in ovarian cancer patients(r=0.48).The combined detection of serum HE4 and CA125 have significant importance in the early diagnosis,determining the degree of malignancy and evaluating the effect of treatment and prognosis of ovarian cancer.
出处 《标记免疫分析与临床》 CAS 2010年第6期368-371,共4页 Labeled Immunoassays and Clinical Medicine
关键词 人附睾蛋白4 CA125 卵巢癌 Human epididymis gene product 4 Cancer antigen 125 Ovarian cancer
  • 相关文献

参考文献13

  • 1Ozols R F,Bookman M A,Connolly D C,et al.Focus on epithelial ovarian cancer[J].Cancer Cell,2004,5:19-24.
  • 2Hellstrom I,Raycraft J,Hayden-Ledbetter,et al.The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma[J].Cancer Res,2003,63(13):3695-3700.
  • 3杨永彬,徐伟,陈建利,万小平.卵巢癌肿瘤标志物研究进展[J].国外医学(妇产科学分册),2004,31(4):229-232. 被引量:24
  • 4Cohen L S,Eseobar P F,Scharm C,et al.Three-dimensional power doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction[J].Gynecol Oncol,2001,84(2):352-353.
  • 5Zhang Z,Barnhill S D,Zhang H,et al.Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses[J].Gynecol Oncol,1999,73:56-61.
  • 6Woolas R P,Xu F J,Jacobs I J,et al.Elevation of multiple serum markers in patients with stage I ovarian cancer[J].J Natl Cancer Inst,1993,85:1748-1751.
  • 7Schutter E M,Davelaar E M,van Kamp G J,et al.The differential diagnostic potential of a panel of tumour markers(CA125,CA15-3,and CA724 antigens)in patients with a pelvic mass[J].Am J Obstet Gynecol,2002,187:385-392.
  • 8Woolas R P,Conaway M R,Xu F,et al.Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses[J].Gynecol Oneol,1995,59:111-116.
  • 9van Haaften-Day C,Shen Y,Xu F,et al.OVX1,macrophage-colony stimulating factor and CA-125-II as tumour markers for epithelial ovarian carcinoma:a critical appraisal[J].Cancer,2001,92:2837-2844.
  • 10Kirchhoff C,Habben I,Ivell R,et al.A major human epididymis specific cdna encodes a protein with sequence homology to extracellular proteinase inhibitors[J].Biol Reprod,1991,45(2):350-357.

二级参考文献20

  • 1Whitehouse C, Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol Oncol, 2003, 88:152-157.
  • 2Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res, 2002,62(13):3609-3614.
  • 3Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomics patterns in serum to identify ovarian cancer. Lancet, 2002, 359:572-577.
  • 4Lloyd KO, Yin BW. Synthesis and secretion of the ovarian cancer antigen CA 125 by the human cancer cell line NIH: OVCAR-3. Tumour Biol,2001, 22(2):77-82.
  • 5Maeda T, Inoue M, Koshiba S, et al. Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125(MUC 16). J Biol Chem, 2004,279(13): 13174-13182.
  • 6Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem, 2001,276(29): 27371-27375.
  • 7Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer, 2000, 82(9): 1535-1538.
  • 8Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2)protein is a biomarker for ovarian carcinoma. Cancer Res, 2003, 63(13): 3695-3700.
  • 9Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem, 2002, 48(8): 1198-1205.
  • 10Yousef GM, Diamandis EP. Expanded human tissue kallikrein family-a novel panel of cancer biomarkers. Turnour Biol, 2002, 23 (3):185-192.

共引文献23

同被引文献119

引证文献12

二级引证文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部